Designing an electrochemical sensor based on ZnO nanoparticle-supported molecularly imprinted polymer for ultra-sensitive and selective detection of sorafenib
This study is the first electrochemical study for the determination of SOR, and thanks to the ZnO NPs supported MIP sensor, it stands out in terms of both high sensitivity and superior selectivity. Also, this designed sensor provides controlled orientation of the template and complete removal of templates in a one-step process, allowing extremely low detection and quantification limits.PMID:37858567 | DOI:10.1016/j.aca.2023.341866 (Source: Analytica Chimica Acta)
Source: Analytica Chimica Acta - October 20, 2023 Category: Chemistry Authors: Ahmet Cetinkaya S Irem Kaya Waleed Alahmad Esen Bellur Atici Sibel A Ozkan Source Type: research
Designing an electrochemical sensor based on ZnO nanoparticle-supported molecularly imprinted polymer for ultra-sensitive and selective detection of sorafenib
This study is the first electrochemical study for the determination of SOR, and thanks to the ZnO NPs supported MIP sensor, it stands out in terms of both high sensitivity and superior selectivity. Also, this designed sensor provides controlled orientation of the template and complete removal of templates in a one-step process, allowing extremely low detection and quantification limits.PMID:37858567 | DOI:10.1016/j.aca.2023.341866 (Source: Analytica Chimica Acta)
Source: Analytica Chimica Acta - October 20, 2023 Category: Chemistry Authors: Ahmet Cetinkaya S Irem Kaya Waleed Alahmad Esen Bellur Atici Sibel A Ozkan Source Type: research
Designing an electrochemical sensor based on ZnO nanoparticle-supported molecularly imprinted polymer for ultra-sensitive and selective detection of sorafenib
This study is the first electrochemical study for the determination of SOR, and thanks to the ZnO NPs supported MIP sensor, it stands out in terms of both high sensitivity and superior selectivity. Also, this designed sensor provides controlled orientation of the template and complete removal of templates in a one-step process, allowing extremely low detection and quantification limits.PMID:37858567 | DOI:10.1016/j.aca.2023.341866 (Source: Analytica Chimica Acta)
Source: Analytica Chimica Acta - October 20, 2023 Category: Chemistry Authors: Ahmet Cetinkaya S Irem Kaya Waleed Alahmad Esen Bellur Atici Sibel A Ozkan Source Type: research
Real-World Effectiveness of Dasatinib Versus Imatinib in Newly Diagnosed Patients With Chronic Myeloid Leukemia
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm associated with the BCR::ABL1 fusion protein resulting in the uncontrolled production of granulocytes.1 In 2022 it was estimated that approximately 8860 people would be diagnosed with CML in the United States.2 Tyrosine kinase inhibitors (TKIs) have dramatically improved the 10-year survival rate of patients with CML from 20% to 80%.3-5 There are four TKIs approved by the US Food and Drug Administration as first-line (1L) therapy for treating patients who have CML: imatinib (2000), dasatinib (2006), nilotinib (2007), and bosutinib (2012). (Source: Clinical Lym...
Source: Clinical Lymphoma, Myeloma and Leukemia - October 19, 2023 Category: Hematology Authors: Andrew J. Klink, Scott J. Keating, John Brokars, Bruce Feinberg, Elias Jabbour Tags: Original Study Source Type: research
Symptomatic acute pancreatitis induced by nilotinib in a patient with chronic myeloid leukaemia
Med Clin (Barc). 2023 Oct 12:S0025-7753(23)00549-3. doi: 10.1016/j.medcli.2023.08.008. Online ahead of print.NO ABSTRACTPMID:37838535 | DOI:10.1016/j.medcli.2023.08.008 (Source: Medicina Clinica)
Source: Medicina Clinica - October 14, 2023 Category: General Medicine Authors: Khadija Mansour Nesrine Ben Sayed Bouraoui Ouni Source Type: research
Prognostic value and immune landscapes of cuproptosis-related lncRNAs in esophageal squamous cell carcinoma
CONCLUSIONS: The above risk score and nomogram can accurately predict prognosis in ESCC patients and provide guidance for chemotherapy and immunotherapy.PMID:37812189 | DOI:10.18632/aging.205089 (Source: Aging)
Source: Aging - October 9, 2023 Category: Biomedical Science Authors: Xiang Zhang Nan Feng Bo Wu Zishun Guo Tiewen Pan Xiandong Tao Hongyang Zheng Wenxiong Zhang Source Type: research
Prognostic value and immune landscapes of cuproptosis-related lncRNAs in esophageal squamous cell carcinoma
CONCLUSIONS: The above risk score and nomogram can accurately predict prognosis in ESCC patients and provide guidance for chemotherapy and immunotherapy.PMID:37812189 | DOI:10.18632/aging.205089 (Source: Aging)
Source: Aging - October 9, 2023 Category: Biomedical Science Authors: Xiang Zhang Nan Feng Bo Wu Zishun Guo Tiewen Pan Xiandong Tao Hongyang Zheng Wenxiong Zhang Source Type: research
Comparison of cutaneous adverse events between second-generation tyrosine kinase inhibitors and imatinib for chronic myeloid leukemia: a systematic review and meta-analysis
CONCLUSION: Eleven trials involving 4502 patients were analyzed in this study. Patients treated with second-generation TKIs were significantly more likely to experience cutaneous adverse events than those treated with imatinib with a relative risk (RR) of 1.62 (95% confidence interval [CI], [1.25-2.09]). Except dasatinib (RR [95% CI], 1.39 [0.75-2.56]), the risk of adverse events was more with second-generation TKIs than with imatinib as follows: nilotinib (2.11 [1.53-2.90]), bosutinib (1.41 [1.07-1.86]), and radotinib (1.87 [1.33-2.63]). Rash was the most common cutaneous adverse event that was observed in 21.6% of cases ...
Source: Acta Oncologica - October 3, 2023 Category: Cancer & Oncology Authors: Seung-Hyeon Cha Kyungim Kim Yun-Kyoung Song Source Type: research
Comparison of cutaneous adverse events between second-generation tyrosine kinase inhibitors and imatinib for chronic myeloid leukemia: a systematic review and meta-analysis
CONCLUSION: Eleven trials involving 4502 patients were analyzed in this study. Patients treated with second-generation TKIs were significantly more likely to experience cutaneous adverse events than those treated with imatinib with a relative risk (RR) of 1.62 (95% confidence interval [CI], [1.25-2.09]). Except dasatinib (RR [95% CI], 1.39 [0.75-2.56]), the risk of adverse events was more with second-generation TKIs than with imatinib as follows: nilotinib (2.11 [1.53-2.90]), bosutinib (1.41 [1.07-1.86]), and radotinib (1.87 [1.33-2.63]). Rash was the most common cutaneous adverse event that was observed in 21.6% of cases ...
Source: Acta Oncologica - October 3, 2023 Category: Cancer & Oncology Authors: Seung-Hyeon Cha Kyungim Kim Yun-Kyoung Song Source Type: research
The Long-term Efficacy and Safety of Nilotinib in Pediatric Patients With CML: a 5-Year Update of the DIALOG Study
Blood Adv. 2023 Sep 22:bloodadvances.2023010122. doi: 10.1182/bloodadvances.2023010122. Online ahead of print.ABSTRACTThe efficacy and safety of nilotinib in pediatric patients with imatinib/dasatinib resistant/intolerant (R/I) or newly diagnosed (ND) Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP) was demonstrated in the phase II, open-label DIALOG study. In this final analysis, long-term efficacy and safety are presented for patients who completed 66 cycles (of 28 days) of treatment with nilotinib (230 mg/m2 twice daily) or discontinued early. Fifty-nine patients were enrolled an...
Source: Adv Data - September 22, 2023 Category: Epidemiology Authors: Nobuko Hijiya Alexey Maschan Carmelo Rizzari Hiroyuki Shimada Carlo Dufour Hiroaki Goto Hyoung Jin Kang Terri Guinipero Zeynep Karakas Francisco Bautista St éphane Ducassou Keon Hee Yoo Christian Michel Zwaan Fr édéric Millot Briana Patterson Jill Sami Source Type: research
Effervescent tablet-assisted deep eutectic solvent based on magnetic nanofluid for liquid phase microextraction of tyrosine kinase inhibitors in plasma samples by high-performance liquid chromatography
CONCLUSIONS: The developed method displayed high sensitivity, low consumption of solvent, low cost, simplicity, high recoveries, short extraction time, and good repeatability for determination of three anti-cancer drugs in human plasma samples.PMID:37717246 | DOI:10.1007/s43440-023-00524-x (Source: Pharmacological Reports)
Source: Pharmacological Reports - September 17, 2023 Category: Drugs & Pharmacology Authors: Khosrou Abdi Maryam Ezoddin Laleh Adlnasab Bahar Aziz Kabiri Mohammad Ali Karimi Somaye Behnamipour Houman Alimoradi Source Type: research